

COPHY 2023 – INDUSTRY SPONSORED SYMPOSIA
March 24-25, 2023, Lisbon, Portugal

FRIDAY MARCH 24, 2023 | HALL A

07:30–08:30	Iveric Bio Pre-Congress Industry Sponsored Breakfast Symposium: Are You Ready for the Future? Treating Geographic Atrophy with Complement Modulation-Based Therapies <i>(Light breakfast will be served from 07:00-07:30 at the entrance of the hall)</i>
Faculty:	Peter K. Kaiser, USA, Baruch D. Kuppermann, USA, Anat Loewenstein, Israel
07:30	Introduction-pre test
07:35	Prevalence, Unmet Need, Impact on Quality of Life
07:40	Imaging Modalities for Assessing Atrophy
07:50	The atrophy is in the details
08:00	A discovery of lesions
08:10	A new era of GA treatments – targeting complement system modulation
08:20	Patient education and setting expectations
08:25	Closing remarks – post-test

FRIDAY MARCH 24, 2023 | HALL A



12:15–13:15	Roche Industry Sponsored Luncheon Symposium: Advancing the management of nAMD via Ang-2/VEGF-A dual inhibition <i>(Lunch boxes served 12:00–12:15)</i>
Chair:	Ângela Carneiro, Portugal
12:15	Welcome and opening remarks Ângela Carneiro, Portugal
12:20	Evidence for Ang-2/VEGF-A inhibition in nAMD: Preclinical and Phase 3 data Rufino Silva, Portugal
12:35	Real-world clinical case discussions James Talks, UK David Almeida, USA Audience Q&A with the panel
13:10	Closing remarks Ângela Carneiro, Portugal

With the [hybrid link](#) you can join the [Roche symposia](#) from the comfort of your clinic / office/ living room and follow the real world case studies that will be shared by the expert panel.

FRIDAY MARCH 24, 2023 | HALL A



16:15–17:15	Roche Industry Sponsored Symposium: Advancing the management of DME via Ang-2/VEGF-A dual inhibition
Chair:	João Figueira , Portugal
16:15	Welcome and opening remarks João Figueira , Portugal
16:20	Evidence for Ang-2/VEGF-A inhibition in DME: Preclinical and Phase 3 data Sara Vaz-Pereira , Portugal
16:35	Real-world clinical case discussions Sobha Sivaprasad , UK David Almeida , USA Audience Q&A with the panel
17:10	Closing remarks João Figueira , Portugal

With the [hybrid link](#) you can join the [Roche symposia](#) from the comfort of your clinic / office/ living room and follow the real world case studies that will be shared by the expert panel.

SATURDAY MARCH 25, 2023 | HALL A



07:30-08:30	Ocular Therapeutix Industry Sponsored Symposium: Sustained-Release TKI Therapies to Address Retinal Vascular Diseases <i>(Light breakfast will be served from 07:00-07:30 at the entrance of the hall)</i>
Chair:	Peter Kaiser , USA
07:30	Welcome and Opening Remarks Peter Kaiser , USA
07:35	The current standard of care for nAMD is ready for disruption: Introduction to tyrosine kinase inhibitors (TKIs) Paolo Lanzetta , Italy
07:45	Emerging TKI therapies in clinical development to treat nAMD Anat Loewenstein , Israel
07:55	OTX-TKI: Clinical trial results Peter Kaiser , USA
08:10	Discussion: Looking into the future – The paradigm shift for retinal vascular diseases Audience Q&A with Panel
08:25	Closing Remarks Peter Kaiser , USA

SATURDAY MARCH 25, 2023 | HALL A



12:15–13:15	AbbVie Industry Sponsored Luncheon Symposium for Healthcare Professionals Only: Controversies in the management of DME & RVO <i>(Lunch boxes served 12:00 -12:15)</i>
Chair:	Anat Loewenstein , Israel
12:15–12:20	Chair's welcome and introduction Anat Loewenstein , Israel
12:20–12:37 12:20 12:25 12:30	Aiming for early disease control can impact long term outcomes For: Maria Vittoria Cicinelli , Italy Against: Matias Igllicki , Argentina Discussion
12:37–12:54 12:37 12:42 12:47	Steroids can be used in suitable patients as first-line treatment For: Peter Addison , UK Against: Faruque Ghanchi , UK Discussion
12:54–13:11 12:54 12:59 13:04	Artificial Intelligence is changing DME & RVO management today For: Bianca Gerendas , Austria Against: Marco Lupidi , Italy Discussion
13:11–13:15	Close Anat Loewenstein , Israel

All [Healthcare Professionals](#) are invited to participate at the [using the hybrid link](#).

Promotional meeting organised and funded by AbbVie. AbbVie Products will be discussed in this meeting.

ALL-ABBV-230101 | March 2023

SATURDAY MARCH 25, 2023 | HALL A



13:30–14:30	Bayer Sponsored Symposium Have we maximised outcomes for our patients, or can we go further with disease control? <i>(Dessert boxes served 13:15 -13:30)</i>
Co-chairs:	Ângela Carneiro , Portugal Anat Loewenstein , Israel
13:30	Welcome and introductions Ângela Carneiro , Portugal
13:35	Have we maximised outcomes for our patients? Marion Munk , Switzerland
13:45	Will targeting new pathways lead to improvements in efficacy outcomes? Michael Stewart , USA
13:55	Is aflibercept 8mg a game changer? Anat Loewenstein , Israel
14:10	Panel Discussion All
14:25	Summary of key learnings Ângela Carneiro , Portugal